<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04777929</url>
  </required_header>
  <id_info>
    <org_study_id>SAHoWMU-CR2020-07-210</org_study_id>
    <nct_id>NCT04777929</nct_id>
  </id_info>
  <brief_title>The Relationship of Phthalate Exposure During Pregnancy and Preeclampsia</brief_title>
  <official_title>The Relationship of Phthalate Exposure During Pregnancy and Preeclampsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Wenzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital of Wenzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phthalates are a group of ubiquitous synthetic endocrine-disrupting chemicals. Fetal and&#xD;
      neonatal periods are particularly susceptible to endocrine disorders, which prenatal exposure&#xD;
      to phthalates causes. There is increasing evidence concerning the potential endocrine&#xD;
      disrupting for phthalate exposure during pregnancy. Prenatal exposure phthalates would&#xD;
      disrupt the level of sex hormone in pregnant women, which results in preeclampsia. The&#xD;
      relationship of prenatal phthalate exposure with maternal and neonatal outcomes in human&#xD;
      beings was often sex-specific associations. Because of the potentially harmful influence of&#xD;
      prenatal phthalate exposure, steps should be taken to prevent or reduce phthalate exposure&#xD;
      during pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Phthalates in urine</measure>
    <time_frame>37 weeks to 40 weeks gestation</time_frame>
    <description>Collect the urine of pregnant women and test the abundance of Phthalates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The female progesterone</measure>
    <time_frame>37 weeks to 40 weeks gestation</time_frame>
    <description>Collect the placenta tissue of pregnant women and test the abundance of estrogen progesterone receptor</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Phthalate Exposure</condition>
  <condition>Preeclampsia</condition>
  <condition>Estrogen</condition>
  <condition>Progestin</condition>
  <arm_group>
    <arm_group_label>healthy pregnant woman</arm_group_label>
    <description>pregnant woman without any disease of pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pregnant woman with preeclampia</arm_group_label>
    <description>pregnant woman with preeclampia but without any other disease of pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>test Phthalates, estrogen and progesterone</intervention_name>
    <description>test mothers Phthalates in their urine, and test estrogen and progesterone receptor in placental tissue</description>
    <arm_group_label>healthy pregnant woman</arm_group_label>
    <arm_group_label>pregnant woman with preeclampia</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participants include pregnant women meeting the inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Term pregnancy with the gestational age of 37-40 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Maternal systemic diseases (hypertension disorders, immunological diseases) or&#xD;
             pregnant complications (polyhydramnios, oligohydramnios, diabetes mellitus,&#xD;
             intrahepatic cholestasis of pregnancy)&#xD;
&#xD;
          -  Delivery before 37 weeks or after 40 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Eligible participants is female.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Hua</last_name>
    <role>Study Director</role>
    <affiliation>Second Affiliated Hospital of Wenzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Hua</last_name>
    <phone>+8613676403165</phone>
    <phone_ext>+8613676403165</phone_ext>
    <email>wzfeyhy1015@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>department of obstetrics of Second Affiliated Hospital of Wenzhou Medical University</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>ying hua, doctor</last_name>
      <phone>+8613676403165</phone>
      <email>wzfeyhy1015@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>February 28, 2021</last_update_submitted>
  <last_update_submitted_qc>February 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

